JP2017506626A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017506626A5 JP2017506626A5 JP2016550471A JP2016550471A JP2017506626A5 JP 2017506626 A5 JP2017506626 A5 JP 2017506626A5 JP 2016550471 A JP2016550471 A JP 2016550471A JP 2016550471 A JP2016550471 A JP 2016550471A JP 2017506626 A5 JP2017506626 A5 JP 2017506626A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- antibody
- antigen
- binding fragment
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461939857P | 2014-02-14 | 2014-02-14 | |
| US61/939,857 | 2014-02-14 | ||
| US201462000162P | 2014-05-19 | 2014-05-19 | |
| US62/000,162 | 2014-05-19 | ||
| US201462025094P | 2014-07-16 | 2014-07-16 | |
| US62/025,094 | 2014-07-16 | ||
| US201462052227P | 2014-09-18 | 2014-09-18 | |
| US62/052,227 | 2014-09-18 | ||
| EP14306729.6 | 2014-10-29 | ||
| EP14306729 | 2014-10-29 | ||
| PCT/US2015/015633 WO2015123423A2 (en) | 2014-02-14 | 2015-02-12 | Methods for treating patients with hypercholesterolemia that is not adequately controlled by moderate-dose statin therapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017506626A JP2017506626A (ja) | 2017-03-09 |
| JP2017506626A5 true JP2017506626A5 (enExample) | 2018-03-15 |
Family
ID=51870958
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016550471A Pending JP2017506626A (ja) | 2014-02-14 | 2015-02-12 | 中程度用量スタチン療法により適切に管理されない高コレステロール血症を有する患者を処置するための方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20150231236A1 (enExample) |
| EP (1) | EP3104879A2 (enExample) |
| JP (1) | JP2017506626A (enExample) |
| KR (1) | KR20160115939A (enExample) |
| CN (1) | CN106029096A (enExample) |
| AU (1) | AU2015217118A1 (enExample) |
| CA (1) | CA2939507A1 (enExample) |
| EA (1) | EA201691320A1 (enExample) |
| MX (1) | MX2016010504A (enExample) |
| WO (1) | WO2015123423A2 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130064834A1 (en) | 2008-12-15 | 2013-03-14 | Regeneron Pharmaceuticals, Inc. | Methods for treating hypercholesterolemia using antibodies to pcsk9 |
| JO3672B1 (ar) | 2008-12-15 | 2020-08-27 | Regeneron Pharma | أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9). |
| BR112013018740A2 (pt) | 2011-01-28 | 2019-01-08 | Sanofi Sa | anticorpos humanos para pcsk9 para uso em métodos de tratamento de grupos específicos de indivíduos |
| AR087305A1 (es) | 2011-07-28 | 2014-03-12 | Regeneron Pharma | Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit |
| CN103930444B (zh) | 2011-09-16 | 2020-08-04 | 瑞泽恩制药公司 | 用前蛋白转化酶枯草溶菌素-9(PCSK9)抑制剂降低脂蛋白(a)水平的方法 |
| US9255154B2 (en) | 2012-05-08 | 2016-02-09 | Alderbio Holdings, Llc | Anti-PCSK9 antibodies and use thereof |
| US10058630B2 (en) | 2012-10-22 | 2018-08-28 | Concievalve, Llc | Methods for inhibiting stenosis, obstruction, or calcification of a stented heart valve or bioprosthesis |
| US20140257473A1 (en) * | 2012-10-22 | 2014-09-11 | Nalini Marie Rajamannan | Methods for inhibiting stenosis, obstruction, or calcification of a stented heart valve or bioprosthesis |
| US10111953B2 (en) | 2013-05-30 | 2018-10-30 | Regeneron Pharmaceuticals, Inc. | Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9) |
| TW202021614A (zh) | 2013-06-07 | 2020-06-16 | 法商賽諾菲生物技術公司 | 藉由投與ｐｃｓｋ９抑制劑抑制動脈粥狀硬化的方法 |
| US10428157B2 (en) | 2013-11-12 | 2019-10-01 | Sanofi Biotechnology | Dosing regimens for use with PCSK9 inhibitors |
| US20230374155A1 (en) * | 2014-05-15 | 2023-11-23 | Rani Therapeutics, Llc | Pcsk9 antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| CA2949236C (en) | 2014-05-15 | 2023-06-13 | Incube Labs, Llc | Pharmaceutical compositions and methods for fabrication of solid masses comprising polypeptides and/or proteins |
| US10689460B2 (en) * | 2014-05-15 | 2020-06-23 | Incube Labs, Llc | PCSK9 antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| MX2017000527A (es) * | 2014-07-14 | 2017-08-10 | Amgen Inc | Formulaciones de anticuerpos cristalinos. |
| KR20230074283A (ko) | 2014-07-16 | 2023-05-26 | 사노피 바이오테크놀로지 | 이형접합성 가족성 고콜레스테롤혈증(heFH) 환자의 치료방법 |
| JP2018523684A (ja) | 2015-08-18 | 2018-08-23 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | リポタンパク質アフェレーシスを受けている高脂血症の患者を治療するための抗ｐｃｓｋ９阻害抗体 |
| AU2016320867B2 (en) * | 2015-09-08 | 2023-03-30 | Rani Therapeutics, Llc | PCSK9 antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| US10939164B2 (en) * | 2016-05-10 | 2021-03-02 | Rovi Guides, Inc. | Method and system for transferring an interactive feature to another device |
| US20190321515A1 (en) * | 2016-06-27 | 2019-10-24 | ConcieValve LLC | Improved methods for inhibiting stenosis, obstruction, or calcification of a stented heart valve or bioprosthesis |
| KR102401796B1 (ko) | 2017-04-13 | 2022-05-25 | 카딜라 핼쓰캐어 리미티드 | 신규의 펩타이드 기재 pcsk9 백신 |
| GB201720162D0 (en) | 2017-12-04 | 2018-01-17 | Univ Oxford Innovation Ltd | Method |
| RS66416B1 (sr) | 2019-01-18 | 2025-02-28 | Astrazeneca Ab | 6'-[[(1s,3s)-3-[[5-(difluorometoksi)-2-pirimidinil]amino]ciklopentil]amino][1(2h),3'-bipiridin]-2-on kao inhibitor pcsk9 i metode njegove primene |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| JO3672B1 (ar) | 2008-12-15 | 2020-08-27 | Regeneron Pharma | أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9). |
| BR112013018740A2 (pt) * | 2011-01-28 | 2019-01-08 | Sanofi Sa | anticorpos humanos para pcsk9 para uso em métodos de tratamento de grupos específicos de indivíduos |
| CN103930444B (zh) * | 2011-09-16 | 2020-08-04 | 瑞泽恩制药公司 | 用前蛋白转化酶枯草溶菌素-9(PCSK9)抑制剂降低脂蛋白(a)水平的方法 |
| US9255154B2 (en) * | 2012-05-08 | 2016-02-09 | Alderbio Holdings, Llc | Anti-PCSK9 antibodies and use thereof |
| EP2854787A4 (en) * | 2012-05-25 | 2016-02-24 | Catabasis Pharmaceuticals Inc | METHODS OF DECREASING PROPANTEIN CONVERTASE SUBTILISINE / KEXINE TYPE 9 (PCSK9) |
-
2015
- 2015-02-12 WO PCT/US2015/015633 patent/WO2015123423A2/en not_active Ceased
- 2015-02-12 US US14/621,000 patent/US20150231236A1/en not_active Abandoned
- 2015-02-12 EA EA201691320A patent/EA201691320A1/ru unknown
- 2015-02-12 JP JP2016550471A patent/JP2017506626A/ja active Pending
- 2015-02-12 MX MX2016010504A patent/MX2016010504A/es unknown
- 2015-02-12 CN CN201580008411.8A patent/CN106029096A/zh active Pending
- 2015-02-12 KR KR1020167022444A patent/KR20160115939A/ko not_active Ceased
- 2015-02-12 CA CA2939507A patent/CA2939507A1/en not_active Abandoned
- 2015-02-12 EP EP15710616.2A patent/EP3104879A2/en not_active Withdrawn
- 2015-02-12 AU AU2015217118A patent/AU2015217118A1/en not_active Abandoned
-
2018
- 2018-06-28 US US16/022,255 patent/US20180296672A1/en not_active Abandoned